Home / News & Events

News & Events

  • Tout
  • Prix
  • Communauté
  • Profil du Réseau
  • Communiqué de presse
  • Points saillants de la recherche
Points saillants de la recherche

Helping our immune system bypass antibiotic resistance

GlycoNet scientists are searching for ways to weaken bacteria’s ability to develop resistance.

Communiqué de presse

GlycoNet Investigators leverage Network project to receive $1.15M in funding for breast cancer research

Funding will enable Drs. Yves St-Pierre, David Chatenet, and Nicolas Doucet to develop a revolutionary immunotherapy against breast cancer.

Points saillants de la recherche

New family of enzymes reveals the Achilles’ heel of fungal pathogens

GlycoNet scientists share findings that could lead to therapeutics to treat fungal infections.


GlycoNet Investigator honoured with prestigious award from the Canadian Society of Microbiologists

Dr. Lori Burrows received the 2020 CSM Murray Award for career achievement.


GlycoNet Scientific Director receives award from American Chemical Society

Dr. Todd Lowary is named a recipient of Arthur C. Cope Late Career Scholars Award.


GlycoNet Investigator recognized with Killam Research Fellowship

McMaster University professor Dr. Eric Brown has been awarded a Killam Research Fellowship.

Communiqué de presse

GlycoNet Welcomes $16.3 Million Renewed Commitment from the Networks of Centres of Excellence for Glycomics Research

Founded in 2015, GlycoNet has been working to develop a collaborative national network to accelerate carbohydrate-based healthcare treatments, vaccine, and technologies for Canadians.

Profil du Réseau

GlycoNet Announces New Chair of the Board of Directors

Ms. Karimah Es Sabar is appointed as Chair of GlycoNet Board of Directors.

Communiqué de presse

Announcement of renewed funding from NCE

The Networks of Centres of Excellence (NCE) announced today the renewed funding for five NCE networks.

Points saillants de la recherche

Preventing hospital-acquired pneumonia

GlycoNet researchers identified a previously unrecognized family of enzymes that put us at risk for deadly diseases.

Communiqué de presse

Glycovax Pharma develops a vaccine against COVID-19

The biopharmaceutical company founded by GlycoNet Investigator is working to develop a semi-synthetic vaccine in the preclinical phase

Communiqué de presse

GlycoNet-affiliated startup company searches for antiviral compounds to treat COVID-19

48Hour Discovery aims to develop clinically useful compounds by December 2020.


en_USEnglish fr_CAFrench
Scroll to Top